Z

Zosano Pharma Corp
F:0ZPN

Watchlist Manager
Zosano Pharma Corp
F:0ZPN
Watchlist
Price: 0.525 EUR Market Closed
Market Cap: €18.9m

Balance Sheet

Balance Sheet Decomposition
Zosano Pharma Corp

Balance Sheet
Zosano Pharma Corp

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021
Assets
Cash & Cash Equivalents
5
6
1
7
15
12
9
6
35
11
Cash Equivalents
5
6
1
7
15
12
9
6
35
11
Short-Term Investments
0
0
0
30
0
0
14
0
0
0
Total Receivables
1
3
0
0
0
0
0
0
0
0
Accounts Receivables
0
0
0
0
0
0
0
0
0
0
Other Receivables
1
3
0
0
0
0
0
0
0
0
Other Current Assets
0
0
0
0
0
2
0
1
0
0
Total Current Assets
6
10
2
37
15
13
23
7
36
12
PP&E Net
1
12
10
8
5
4
12
30
36
36
PP&E Gross
1
0
10
8
0
0
12
30
36
36
Accumulated Depreciation
2
0
20
22
0
0
26
27
28
30
Long-Term Investments
12
0
0
0
0
0
0
0
0
0
Other Long-Term Assets
0
1
2
0
0
0
1
0
0
0
Total Assets
20
N/A
22
+12%
13
-40%
45
+240%
21
-54%
18
-14%
36
+99%
38
+5%
72
+91%
48
-33%
Liabilities
Accounts Payable
0
3
1
1
1
2
4
4
2
2
Accrued Liabilities
0
3
3
2
2
2
5
7
7
5
Short-Term Debt
0
1
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
3
9
3
6
7
2
5
6
4
Other Current Liabilities
3
1
0
0
0
0
0
0
0
0
Total Current Liabilities
4
12
13
7
10
10
11
16
15
11
Long-Term Debt
9
10
13
12
7
0
5
6
5
1
Other Liabilities
1
0
0
0
0
1
1
6
5
3
Total Liabilities
14
N/A
22
+59%
27
+24%
19
-30%
16
-13%
11
-33%
17
+56%
28
+66%
25
-13%
15
-37%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
Retained Earnings
119
124
138
167
197
226
261
299
332
362
Additional Paid In Capital
125
125
125
193
201
233
280
308
380
395
Other Equity
0
0
0
0
0
0
0
0
0
0
Total Equity
6
N/A
0
-92%
13
N/A
27
N/A
4
-83%
7
+57%
19
+165%
9
-50%
48
+406%
33
-31%
Total Liabilities & Equity
20
N/A
22
+12%
13
-40%
45
+240%
21
-54%
18
-14%
36
+99%
38
+5%
72
+91%
48
-33%
Shares Outstanding
Common Shares Outstanding
1
1
0
1
1
2
12
24
102
3
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett